Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy

Thrombosis and Haemostasis

Volumn 75, Issue 2, 1996, Pages 219-223

  Mitusch, Rolf ^a   Siemens, Hans J ^a   Garbe, Michael ^a   Wagner, Thomas ^a   Sheikhzadeh, Abdolhamid ^a   Diederich, Karl W ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN III; FIBRIN MONOMER; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK; SINUS RHYTHM; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM;

EID: 0029990228     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650247     Document Type: Article

References (26)

1. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57.
2. EAFT Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 1993; 342: 1255-62.
3. Daniel WG, Nellesen U, Schröder E, Nonnast-Daniel B, Bednarski P, Nikutta P, Lichtlen PR. Left atrial spontaneous echo contrast in mitral valve disease: an indicator for an increased thromboembolic risk. J Am Coll Cardiol 1988; 11: 1204-11.
4. Black IW, Hopkins AP, Lee LCL, Walsh WF. Left atrial spontaneous echo contrast: A clinical and echocardiographic analysis. J Am Coll Cardiol 1991; 18: 398-404.
5. Mitusch R, Lange V, Stierle U, Maurer B, Sheikhzadch A. Transesophageal echocardiographic determinants of embolism in nonrheumatic atrial fibrillation. Int J Card Imaging 1995; 11: 27-34.
6. Mügge A, Kühn H, Nikutta P, Grote J, Lopez JAG, Daniel WG. Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with nonrheumatic atrial fibrillation: Identification of a subgroup of patients at increased embolic risk. J Am Coll Cardiol 1994; 23: 599-607.
7. Mitusch R, Garbe M, Schmücker G, Schwabe K, Stierle U, Sheikhzadeh A. Relation of left atrial appendage function to the duration and reversibility of non-valvular atrial fibrillation. Am J Cardiol 1995; 75: 944-7.
8. Gustafsson C, Blombäck M, Britton M, Hamsten A, Svensson J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke 1990; 21: 47-51.
9. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: Insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-50.
10. Contant G, Gouault-Heilmann M, Martinoli JL. Heparin inactivation during blood storage: Its prevention by blood collection in citric acid, theophylline, adenosine, dipyridamol - C.T.A.D. Mixture. Thromb Res 1983; 31: 365-74.
11. Kistler JP, Singer DE, Millensen MM, Bauer KA, Gress DR, Barzegar S, Hughes RA, Sheehan MA, Maraventano SW, Oertel LB, Rosner B, Rosenberg RD, for the BAATAF Investigators. Effect of low-intensity warfarin anticoagulation on level of activity of the hemostatic system in patients with atrial fibrillation. Stroke 1993; 24: 1360-5.
12. Kumagai K, Fukunami M, Ohmori M, Kitabatake A, Kamada T, Hoki N. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. J Am Coll Cardiol 1990; 16: 377-80.
13. Uno M, Tsuji H, Sawada S, Toyoda T, Nakagawa M. Fibrinopeptide A (FPA) levels in atrial fibrillation and the effects of heparin administration. Jpn Circ J 1988; 52: 9-12.
14. Asakura H, Hifumi S, Jokaji H, Saito M, Kumabashiri I, Uotani C, Morishita E, Yamzaki M, Shibata K, Mizuhashi K. Prothrombin fragment F1+ 2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation. Blood Coagul Fibrinolysis 1992; 3: 469-73.
15. Bauer KA, Weiss LM, Sparrow D, Vokonas PS, Rosenberg RD. Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative aging study. J Clin Invest 1987; 80: 1527-34.
16. Black IW, Chesterman CN, Hopkins AP, Lee LCL, Chong BH, Walsh WF. Hematologic correlates of left atrial spontaneous echo contrast and thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol 1993; 21: 451-7.
17. Takano K, Yamaguchi T, Ucida K. Markers of a hypercoagulable state following acute ischemic stroke. Stroke 1992; 23: 194-8.
18. Bounameaux H, de Moerloose P, Perrier A, Reber G. Plasma measurement of D-dimer as diagnostic aid in suspected venous thromboembolism: An overview. Thromb Haemost 1994; 71: 1-6.
19. Elias A, Bonfils S, Daoud-Elias M, Gauthier B, Sié P, Boccalon H, Boneu B. Influence of long term oral anticoagulants upon prothrombin fragment 1+2, thrombin-antithrombin III complex and D-dimer levels in patients affected by proximal deep vein thrombosis. Thromb Haemost 1993; 69: 302-5.
20. Takano K, Lino K, Ibayashi S, Tagawa K, Sadoshima S, Fujishima M. Hypercoagulable state under low-intensity warfarin anticoagulation assessed with hemostatic markers in cardiac disorders. Am J Cardiol 1994; 74: 935-39.
21. Millensen MM, Bauer KA, Kistler JP, Barzegar S, Tulin L, Rosenberg RD. Monitoring "mini-intensity" anticoagulation with warfarin: Comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment F1+2 levels. Blood 1992; 79: 2034-8.
22. Bounameaux H, Lijnen HR, Hellemans H, Verstraete M. Effect of standard and low-molecular weight heparin fractions on fibrinolysis and platelet aggregation in patients undergoing hysterectomy. Thromb Haemost 1986; 55: 298.
23. Agnelli O, Borm J, Cosmi B, Levi M, ten Cate JW. Effects of Standard heparin and a low molecular weight heparin (Kabi 2165) on fibrinolysis. Thromb Haemost 1988; 60: 311-3.
24. Grulich-Henn J, Loechelt K, Speiser W, Müller-Berghaus G. Increased tissue-plasminogen activator levels in patients under oral anticoagulant therapy. Blut 1989; 58: 39-42.
25. Falanga A, Barbui T, Rickles FR, Levine MN. Guidelines for clotting studies in cancer patients. Thromb Haemost 1993; 70. 540-2.
26. Zabalgoitia M, on behalf of the SPAF Investigators. Stroke Prevention in Atrial Fibrillation III and transesophageal echo study. Design and progress report (abstr). Eur Heart J 1994; 15: 28.